Bazedoxifene, a selective estrogen receptor modulator is thought to have effective anti-tumoral properties for pancreatic cancer via IL-6 pathway (GP130/STAT3) inhibition.
The objective is to measure IL-6 (GP130/STAT3)-pathway modification on metastasis biopsy of patients with metastatic pancreatic adenocarcinoma before and after treatment with bazedoxifene in addition to chemotherapy.
This study is a single-center, prospective, nonrandomized trial.

Start Date01 Feb 2022

Sponsor / Collaborator

Hopital Fribourgeois

EUCTR2021-005247-78-CZ

/ Not yet recruitingPhase 2

A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability of bazedoxifene, concentrated solution for nebulization (BAZE-X1) in addition to Standard of Care in hospitalized COVID-19 patients suffering from moderate to severe Pneumonia.

Start Date15 Dec 2021

Sponsor / Collaborator-

NCT04821141

/ Active, not recruitingPhase 2IIT

Randomized IIB Study of the Effect of Bazedoxifene Plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer

Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine needle aspiration (RPFNA). Change in biomarkers will be compared between groups.

Start Date14 Dec 2021

Sponsor / Collaborator

University of Kansas

[+1]

100 Clinical Results associated with Bazedoxifene

100 Translational Medicine associated with Bazedoxifene

100 Patents (Medical) associated with Bazedoxifene

516

Literatures (Medical) associated with Bazedoxifene

01 Sep 2026·BIOORGANIC CHEMISTRY

Design, synthesis, in vitro and in silico evaluation of novel 5-(1-benzyl-1H-indol-3-yl)-3-phenyl-4,5-dihydroisoxazole derivatives against ER-positive breast cancer

Article

Author: Kaur, Kamalpreet ; Midha, Tushar ; Mayank ; Baranwal, Somesh ; Jaitak, Vikas ; Das, Agnidipta

Estrogen receptor alpha (ERα) overexpression is the primary dominant factor responsible for breast cancer (BC) development. Despite survival success, clinical use of anti-estrogenic agents is hindered by endometrial risk, thromboembolic complications, and rising drug resistance. Therefore, novel, more potent ERα-targeted agents are essential to reduce the BC burden. A series of 21 5-(1-benzyl-1H-indol-3-yl)-3-phenyl-4,5-dihydroisoxazole hybrids were designed, synthesized, and evaluated in vitro on ERα-predominant and triple-negative cells. The structural and biological novelty of the designed backbone was confirmed through searches of the SciFinder and PubChem databases. Hybrids 19 (MCF-7, IC₅₀ = 13.1 ± 0.0711 μM), 20 (T-47D, IC₅₀ = 9.666 ± 0.059 μM), and 21 (T-47D, IC₅₀ = 13.19 ± 0.0416 μM) were identified as promising candidates against ER+ BC. Compounds 19 and 21 underscored significant human ERα inhibition in contrast to tamoxifen and bazedoxifene. In the cytotoxicity study, compound 21 exhibited a selectivity index higher than bazedoxifene, 12.4-fold in T-47D, and 4.4-fold in MCF-7, indicating low healthy cell toxicity. Compounds 19, 20, and 21 demonstrated cell cycle arrest predominantly at the G0/G1 checkpoint to induce apoptosis. Compound 21 was observed with the highest early and total apoptotic effect. In addition, MD simulations confirmed stable ERα binding for compounds 19 and 21 with low average RMSD and RMSF values, while compound 20 formed the most compact complex. Moreover, pharmacokinetics and DFT analysis ensured drug-likeness and bio-feasibility of promising molecules. Finally, based on interaction-analysis, bio-assay findings, and 3D-QSAR mapping, an overall structure-activity correlation was established for future-optimization and lead-development of indole - 4,5-dihydroisoxazole hybrids against ER+ BC.

01 Jul 2026·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A predictive insight into the ATRNL1-mediated ceRNA network driving abdominal aortic aneurysm progression via VSMC phenotypic switching

Article

Author: Zhang, Lusha ; Wang, Weiying ; Yu, Qi ; Liu, Jiping ; Su, Peihong ; Chen, Xiaochang ; Guan, Hua ; Wang, Chuan ; Wang, Han ; Chao, Yinping ; Wang, Xiaoyan ; Du, Juan ; Zhang, Yujie ; Xiang, Aoqi

OBJECTIVE:

Current therapeutic options for abdominal aortic aneurysm (AAA) are primarily invasive and carry significant risks, highlighting an urgent need for non-invasive pharmacological strategies. This study aimed to identify a novel ceRNA axis driving AAA progression and to explore potential therapeutic agents through systematic drug repositioning.

METHODS:

Transcriptomic data from human AAA (GSE183464) and a vascular smooth muscle cell (VSMC) phenotypic switching dataset (GSE77278) were integrated. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were employed to identify an ATRNL1-centered ceRNA axis. Mechanistic interactions were validated through histological and immunofluorescence analyses. Systematic screening of the DSigDB database identified drug repositioning candidates, followed by network pharmacology analysis. The predicted targets and mechanisms were further validated via wet-lab experiments in both primary human and mouse VSMCs.

RESULTS:

Analysis revealed a significant downregulation of the ATRNL1/hsa_circ_0020097 axis in both AAA tissues and phenotypically modulated VSMCs. Mechanistically, hsa_circ_0020097 functions as a molecular sponge for hsa-miR-3185, and its downregulation enhances miR-3185-mediated repression of the key target gene LPP. Histopathological examination confirmed classic AAA hallmarks, including elastic lamina degradation and medial thickening, accompanied by a marked reduction in the co-localization of LPP and the VSMC marker α-SMA, which correlated with disease severity. Notably, qPCR validation in primary human aortic VSMCs (HAVSMCs) and mouse VSMCs confirmed that the entire ATRNL1/hsa_circ_0020097/miR-3185/LPP axis exhibits synchronized expression fluctuations under AAA-related stress. Drug repositioning identified Bazedoxifene as the top candidate. In vitro experiments demonstrated that Bazedoxifene significantly restores the expression of this ceRNA axis in both human and mouse cells, with optimal effects observed at 10 μM.

CONCLUSION:

This study elucidates a novel ATRNL1/hsa_circ_0020097/miR-3185/LPP ceRNA axis that promotes AAA development by driving VSMC phenotypic switching. Our findings suggest that Bazedoxifene exerts protective effects by targeting the ATRNL1 axis to modulate VSMC phenotypes. This work not only uncovers a previously unrecognized pathogenic axis in AAA but also provides a directly translatable pharmacological strategy for its clinical management.

01 Apr 2026·CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Menopausal hormone therapy and breast cancer: risk and management

Article

Author: Sanserino, Kathryne

Purpose of review:

Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause (GSM), yet concerns about breast cancer risk continue to limit its use. This review summarizes contemporary evidence regarding breast safety in healthy women and breast cancer survivors, with attention to emerging therapies and special populations.

Recent findings:

Long-term data show that estrogen-alone therapy after hysterectomy does not increase breast cancer incidence and is associated with reduced mortality, while combined estrogen–progestogen therapy carries a small, duration-dependent increase in risk. Risk varies by progestogen, with micronized progesterone demonstrating a more favorable profile than synthetic progestins. Conjugated estrogens with bazedoxifene improve symptoms and bone density without increasing mammographic density, though long-term oncologic outcomes are unknown. In breast cancer survivors, evidence of harm comes from randomized trials of combined estrogen–progestogen therapy and tibolone; estrogen-alone therapy has not been tested in randomized trials in this population. For GSM, low-dose vaginal estrogen is effective and has not been associated with higher recurrence or mortality in most survivors; aromatase inhibitor users warrant shared decision-making. Nonhormonal therapies, including neurokinin-3 receptor antagonists, offer effective systemic alternatives when hormone therapy is contraindicated or declined.

Summary:

Most healthy women can use hormone therapy safely with individualized counseling, attention to timing, and progestogen selection. Among survivors, low-dose vaginal estrogen remains appropriate for refractory GSM with oncology involvement.

News (Medical) associated with Bazedoxifene

12 Dec 2025

·www.drugs.com

SABCS: Menopausal Hormone Therapy Does Not Increase Breast Cancer Risk in BRCA Carriers

FRIDAY, Dec. 12, 2025 -- Use of menopausal hormone therapy (MHT) following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 9 to 12 in San Antonio. Joanne Kotsopoulos, Ph.D., from the Women's College Hospital Research and Innovation Institute in Toronto, and colleagues conducted a prospective matched analysis of MHT use following menopause (predominantly surgical) and breast cancer risk in BRCA carriers. Women who initiated MHT (exposed) after menopause were matched to women who had not initiated MHT (unexposed) by gene, year of birth, and age at menopause; data were included for 676 matched pairs. The researchers identified 87 incident breast cancer cases in the exposed group and 128 in the unexposed group (12.9 versus 18.9 percent) after a mean follow-up of 5.6 years from the date of first MHT use in exposed women. Women who used estrogen experienced a significant reduction in the risk for breast cancer compared with unexposed matched controls (hazard ratio, 0.37). No protective or adverse effect was seen for use of estrogen plus progestogen, for progestogen alone, or for tibolone. In the 43 women who used a conjugated equine estrogen plus bazedoxifene, there were no diagnoses of breast cancer. The findings were similar for carriers of either gene. "Our findings suggest that clinicians should take a personalized approach to menopause management for women with BRCA mutations who are suffering from the impact of surgical (or natural) menopause, if there are no contraindications for them," Kotsopoulos said in a statement. Press Release More Information

Clinical Result

14 Oct 2025

·www.drugtopics.com

White House Strikes Deal with Pfizer for Lower Drug Prices, Online DTC Website

Amid ongoing approaches to lower drug prices for US patients, like the Most-Favored-Nation policy, this is another partnership the Trump Administration believes will improve access challenges. The Trump Administration is set to team up with Pfizer in a partnership that would bring lower prices for the manufacturer’s drugs as well as a direct-to-consumer (DTC) website for patients to purchase them, which the White House is naming “TrumpRx.”1 While the rollout of this new partnership is still in its beginning stages, Pfizer is the first drugmaker to provide actionable steps in lowering US drug prices across the board,2 an initiative perpetuated by the signing of the Most-Favored-Nation (MFN) Prescription Drug Pricing Executive Order.3 “It’s a win for American patients, a win for American leadership, and it’s a win for Pfizer because it provides the certainty and stability we need to continue advancing new breakthrough medicines for patients,” said Pfizer spokeswoman Amy Rose, according to The Wall Street Journal.2 Despite early reports of the Pfizer program providing a decrease in drug prices for Medicaid patients, there is potential for savings to reach the pockets of all US patients and consumers as President Trump continues to put pressure on manufacturers. On top of this most recent Pfizer-White House partnership, as well as provisions backed by the MFN policy, the potential impact of pharmaceutical tariffs could add a third layer to the evolution of drug prices in the US. With the new partnership, Pfizer will receive a 3-year grace period on being susceptible to Trump’s pharmaceutical tariffs, which are expected to take effect October 1. “The agreement on lower prices will cover ‘a large majority’ of Pfizer's primary care medicines, along with specialty brand-name drugs, which will be offered at discounts averaging 50% and reaching as high as 85%, a spokesperson for the company said,” according to NBC News.1 Some of the drugs correspondents close to the partnership have named for future price reductions include the menopause medication Duavee (conjugated estrogens/bazedoxifene), Toviaz (fesoterodine fumarate) for treating overactive bladder, and Pfizer’s Eucrisa (crisaborole) skin ointment.4-6 On top of these, and whatever additional drugs that Pfizer already markets, all new drugs that the company introduces will also be sold at lower prices.1 Alongside the announcement of this unprecedented partnership, the administration is set to roll out its “TrumpRx” DTC website for patients across the country to access necessary prescription medications. The website will be fully owned and operated by the US government as well as giving it the federal power to negotiate the prices of DTC drugs themselves.2 The extent of which drugs will be offered and at what type of discounts through the TrumpRx website is currently unknown. There is also uncertainty regarding what patient populations and insurance coverage would be set aside to reap the benefits of these discounts and savings. However, according to Pfizer and White House spokespeople who reported to The Wall Street Journal, the new partnership is projected to benefit as many as 100 million US patients. “Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations,” said Trump, according to Politico.7 Amid the administration’s ongoing commitment to lower US drug prices, they are looking to get US consumers on a level playing field with consumers in other, developed nations. Hence, the MFN drug policy; this was signed as an executive order in June of this year and plainly states that multiple federal agencies should “take specific actions aimed at compelling drug manufacturers to lower drug prices in the United States in a manner comparable with other ‘developed nations.’”3 From the MFN drug policy to prospective pharmaceutical tariffs and a key partnership between the federal government and a major US drug manufacturer, there is significant movement from the Trump Administration to recorrect the rate of rising drug costs in the US. Many experts in the pharmacy and pharmaceutical industry have expressed disagreement and uncertainty regarding the aforementioned provisions, partnerships, and policies. However, with the continued fight stemming from the administration’s goal to lower drug prices, patients can be hopeful for discounted savings as these programs roll out.1 “President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans,” concluded White House spokesman Kush Desai, according to The Wall Street Journal.2 “Democrats talked the talk for decades about drug prices, but only President Trump is actually walking the walk.” The content above comes from the network. if any infringement, please contact us to modify.

Innovative Drug

01 Oct 2025

·www.pharmaceutical-technology.com

Pfizer shakes hands with White House on drug discounts under MFN programme

A press conference was held in the Oval Office to announce the deal between Pfizer and the US Government. Image credit: Win McNamee / Staff via Getty Images. Pfizer is the first in what could be a string of pharmaceutical companies to come to an agreement with the White House to reduce US drug prices. As part of President Trump’s Most Favored Nation (MFN) policy , the company agreed to ensure that US patients are paying less for prescription medicines, with primary care treatments and some select speciality brands set to be offered at savings that will range as high as 85% and an average of 50%. The MFN policy has been set up by Trump’s administration to tie drug prices in the US to those paid elsewhere in the world. These savings will be accessible through both Medicaid and the federal direct purchasing platform TrumpRx.gov. It was also announced that all new medications from Pfizer will be sold at MFN levels. In a 30 September press conference, Trump said: “For many years, Americans have paid the highest prices anywhere in the world for prescription drugs. The major reason is that American consumers have been subsidising research and development costs for the entire planet. They put all of that on us, and yet they were the beneficiaries, so that is being changed as of today.” Discounts, shown on a poster during the press conference, include an 80% discount on Eucrisa (crisaborole), an 85% discount on Duavee (conjugated estrogens/bazedoxifene), 50% off Zavzpret (zavegepant), and 40% off Xeljanz (tofacitinib). GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The agreement includes a three-year grace period that excludes Pfizer from facing tariffs, as long as the promised $70bn investment into US manufacturing goes ahead. In the press conference, Pfizer CEO Albert Bourla said: “This is a historic day – we are turning the tide and reversing an unfair situation. For years, other rich nations have refused to pay their fair share for medical innovation. This is changing today with this agreement.” While Pfizer is the first to have come to this agreement with the US Government, Trump said that agreements with other pharmaceutical companies could happen in the next few weeks. GlobalData research analyst Cyrus Fan said: “The Trump administration has said the Pfizer deal is the first in a series of deals it intends to secure for the US. This implies more companies will agree to MFN pricing. It is also clear that the Trump administration is easing implementation of MFN by introducing IRP in Medicaid first, leaving room for expansion in the future.” GlobalData is the parent company of Clinical Trials Arena. For those who do not agree to increase the US manufacturing presence and make price agreements with the federal government, President Trump has threatened a 100% tariff on pharmaceutical goods. In a post on his social media network, TruthSocial, on 25 September, President Trump said: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. ‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.” This all comes amid a potential government shutdown, with Democrats accusing the Republicans of approving cuts to the Medicaid programme and other health safety nets that could leave millions of US citizens uninsured in the next ten years. Editor’s note: Comments from GlobalData analyst Cyrus Fan have been added. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

100 Deals associated with Bazedoxifene

External Link

KEGG	Wiki	ATC	Drug Bank
-	Bazedoxifene	G03XC02	DB06401

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	European Union	Pfizer Europe MA EEIG	17 Apr 2009
Osteoporosis, Postmenopausal	Iceland	Pfizer Europe MA EEIG	17 Apr 2009
Osteoporosis, Postmenopausal	Liechtenstein	Pfizer Europe MA EEIG	17 Apr 2009
Osteoporosis, Postmenopausal	Norway	Pfizer Europe MA EEIG	17 Apr 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endometrial Hyperplasia	Phase 3	United States	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Argentina	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Australia	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Chile	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Colombia	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Denmark	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Finland	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Hungary	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	Mexico	Pfizer Inc.	01 Jan 2009
Endometrial Hyperplasia	Phase 3	New Zealand	Pfizer Inc.	01 Jan 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02237079 (BIM, CTgov)	Phase 4	Glucose Intolerance \| Obesity	17	Placebo Oral Tablet	kbqwnqncnc(jkztwaktzo) = nmossugrnr fhrjnzhkcb (mqozbxtvcl, alsecjzgvs - ipnwgffnhh) View more	-	26 Jun 2023
NCT02448771 (Pubmed)	Phase 2	Hormone receptor positive breast cancer	36	Bazedoxifene plus Palbociclib	kikhgicsxi(undqiapluh) = jsigecwdmp ompmbtsvlk (ucuedlpdyn ) View more	Positive	10 Oct 2022
NCT02602704 (Pubmed \| Arthritis Res Ther)	Phase 4	Rheumatoid Arthritis	114	Bazedoxifene + calcium and vitamin D	jvfypyeeot(jldyvxsxll) = lvyaohynmy lnoqcbdpqr (ynyswtolbm )	-	02 Jul 2021
NCT02602704 (Pubmed \| Arthritis Res Ther)	Phase 4	Rheumatoid Arthritis	114	Calcium and vitamin D only	jvfypyeeot(jldyvxsxll) = extpzafymv lnoqcbdpqr (ynyswtolbm, 0.0003 - 0.026)	-	02 Jul 2021
NCT02448771 (CTgov)	Phase 1/2	Hormone receptor positive breast cancer \| Metastatic breast cancer \| Invasive Mammary Carcinoma	36	Bazedoxifene+Palbociclib	fyhkkccfxj = udwcqbdrdv eaxvfpkkid (vizmdyewdk, mxhwbalnrm - jfqrptnyue) View more	-	01 Jul 2021
PD1-05 (SABCS2019)	Phase 1/2	Hormone receptor positive breast cancer ER+ \| HER2-	36	Bazedoxifene 40mg + Palbociclib 125mg	pzejwtepxz(qsedbiyaqr) = axtiapkxqu ygltxxlszg (yfzuiowpqk, 23 - 49) View more	Positive	15 Feb 2019
WCO_IOF_ESCEO2015	Phase 4	Osteoporosis, Postmenopausal	24	Bazedoxifene 20 mg	ivirstukkz(chzysehmhv) = iikobeajwa ezwdrutosd (tqbwicmdlc )	-	17 Apr 2015
NCT00808132 (Selective estrogens, Menopause, And Response to Therapy-5, CTgov)	Phase 3	Endometrial Hyperplasia \| Osteoporosis, Postmenopausal	1,886	Bazedoxifene (Bazedoxifene 20 mg / Conjugated Estrogens 0.45 mg)	sgjihxuesq = sauxqjydpw wmxxrxfzbh (amsvtnhfzo, fgcifimiaw - nrvotwtqvt) View more	-	20 Dec 2013
	Phase 3	Endometrial Hyperplasia \| Osteoporosis, Postmenopausal	1,886	Bazedoxifene (Bazedoxifene 20 mg / Conjugated Estrogens 0.625 mg)	sgjihxuesq = vggcqgbeda wmxxrxfzbh (amsvtnhfzo, boogujtlym - rdvqhdvwdu) View more	-	20 Dec 2013
NCT00205777 (CTgov)	Phase 3	Osteoporotic Fractures \| Osteoporosis	7,609	Bazedoxifene (Bazedoxifene 20 mg (Core+SE I))	xxwqiqjiac = ybhonsucii jpzwdicymv (bxixrtbztd, vznfyhnmui - yrthjdtjxz) View more	-	10 Apr 2013
NCT00205777 (CTgov)	Phase 3	Osteoporotic Fractures \| Osteoporosis	7,609	Bazedoxifene (Bazedoxifene 40 mg (Core))	xxwqiqjiac = ftvvdzcpbi jpzwdicymv (bxixrtbztd, tiprgperpz - xyncwyuptu) View more	-	10 Apr 2013
NCT00238745 (Pubmed \| J Bone Miner Res)	Phase 2	Osteoporosis, Postmenopausal	429	Bazedoxifene 20 mg	ytsdclhcto(mmhzguqbnk) = yeatvhzgbu zjllnetygi (qchlekkerd )	-	01 Mar 2011
NCT00238745 (Pubmed \| J Bone Miner Res)	Phase 2	Osteoporosis, Postmenopausal	429	Bazedoxifene 40 mg	ytsdclhcto(mmhzguqbnk) = gvjujccdgi zjllnetygi (qchlekkerd )	-	01 Mar 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bazedoxifene

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation